비인슐린 당뇨병 치료제 시장

Global Non-Insulin Diabetes Therapeutics Market to Reach US$92.1 Billion by 2030

The global market for Non-Insulin Diabetes Therapeutics estimated at US$49.7 Billion in the year 2023, is expected to reach US$92.1 Billion by 2030, growing at a CAGR of 9.2% over the analysis period 2023-2030. DPP4 Inhibitors, one of the segments analyzed in the report, is expected to record a 10.3% CAGR and reach US$37.9 Billion by the end of the analysis period. Growth in the GLP-1 Receptor Agonists segment is estimated at 9.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.5 Billion While China is Forecast to Grow at 12.9% CAGR

The Non-Insulin Diabetes Therapeutics market in the U.S. is estimated at US$13.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$19.5 Billion by the year 2030 trailing a CAGR of 12.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.8% and 7.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.3% CAGR.

Global Non-Insulin Diabetes Therapeutics Market - Key Trends & Drivers Summarized

Why Are Non-Insulin Diabetes Therapeutics Gaining Traction?

The global healthcare landscape is witnessing a rapid evolution in the treatment of diabetes, with a particular focus on non-insulin therapeutics. This surge in interest is rooted in the need for alternative treatments to insulin, which, despite its efficacy, presents several challenges for patients such as the need for regular injections, risk of hypoglycemia, and lifestyle disruptions. Non-insulin therapies, which include drugs like metformin, GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors, offer a more convenient and sometimes safer alternative for Type 2 diabetes patients. These drugs work by enhancing the body’s insulin sensitivity, reducing glucose production, and promoting the excretion of excess glucose. For millions of patients, these oral or injectable medications reduce the reliance on insulin injections, thus improving compliance and overall quality of life. Recent clinical trials have also shown that certain non-insulin therapies not only help control blood glucose levels but can also reduce cardiovascular risks, a significant concern for diabetic patients. As cardiovascular diseases are the leading cause of mortality in diabetic patients, this dual benefit has been a major factor in the increasing adoption of non-insulin therapeutics globally.

Furthermore, as the global prevalence of Type 2 diabetes continues to rise due to aging populations, urbanization, and lifestyle factors such as poor diet and lack of exercise, healthcare systems are under pressure to provide more cost-effective and scalable treatment options. Non-insulin therapies, being less invasive and more easily administered than insulin injections, represent a compelling solution in both developing and developed markets. Another reason these therapies are gaining traction is the growing recognition among healthcare professionals of the long-term benefits they offer in terms of patient quality of life. The convenience of oral tablets, as opposed to frequent injections, significantly improves patient adherence to treatment regimens, which is critical for the management of a chronic condition like diabetes. Moreover, non-insulin drugs often come with a lower risk of weight gain, another factor that has made them a preferred option for many patients and clinicians alike.

What Role Does Innovation Play In Shaping This Market?

Technological innovation is at the heart of the growing non-insulin diabetes therapeutics market. Pharmaceutical companies are increasingly focusing on the development of combination therapies that utilize multiple mechanisms to control blood sugar levels effectively. For example, a growing trend is the use of SGLT2 inhibitors in combination with GLP-1 receptor agonists, which targets glucose regulation from both ends—preventing glucose reabsorption by the kidneys while stimulating insulin production in the pancreas. This dual-action approach not only helps in better glucose control but also addresses multiple facets of Type 2 diabetes, such as weight management and cardiovascular risk. Another significant area of innovation is the formulation of extended-release medications that allow for less frequent dosing, which greatly improves patient compliance. Once-weekly injectables, like those in the GLP-1 class, have been particularly popular, offering patients more freedom and flexibility in managing their condition. This focus on patient-centric innovations has played a crucial role in driving the adoption of non-insulin therapies.

Furthermore, research is now pushing the boundaries beyond traditional mechanisms, exploring novel ways to target diabetes. One such frontier is the use of gut microbiome therapies, which aim to regulate blood glucose levels by altering the bacterial composition in the digestive tract. These therapies, still largely in clinical trials, offer the potential for non-invasive, long-term management of diabetes by leveraging the body's natural processes. Another exciting development is the exploration of gene-editing technologies, such as CRISPR, which could one day provide a permanent solution for diabetes by correcting the underlying genetic causes of insulin resistance or beta-cell dysfunction. As these innovations progress, they are expected to not only expand the range of therapeutic options available to patients but also revolutionize the way diabetes is treated. The ongoing integration of digital health tools, such as continuous glucose monitors (CGMs) that work in tandem with non-insulin therapies, is also creating a more connected, data-driven approach to diabetes management, enabling more personalized and precise treatment plans.

How Do Consumer Preferences Drive The Non-Insulin Therapeutics Market?

Patient preferences and behaviors are crucial drivers of growth in the non-insulin diabetes therapeutics market. A noticeable shift has been observed among diabetes patients, with many favoring non-insulin medications due to their ease of use and fewer associated side effects. The global increase in diabetes prevalence, largely fueled by urbanization, sedentary lifestyles, and rising obesity rates, has heightened the demand for simpler, more manageable treatment regimens. Many patients are drawn to non-insulin therapies because of the convenience of oral administration or less frequent injections compared to daily insulin use. Additionally, the lower risk of hypoglycemia—a potentially dangerous side effect of insulin therapy—makes non-insulin drugs particularly appealing. As diabetes management increasingly becomes a part of routine daily life for millions, patients are seeking therapies that offer flexibility, fewer restrictions on diet and activity, and lower costs. This consumer demand for more convenient, lifestyle-friendly treatments is a powerful force driving the development and adoption of non-insulin therapeutics.

Moreover, an increasing number of patients are becoming more engaged in their healthcare decisions, with access to information about the latest treatment options readily available through digital health platforms and telemedicine. This empowerment is further encouraging the shift toward non-insulin therapies, as patients become more informed about their choices and prioritize treatments that align with their lifestyle preferences. Another significant factor influencing consumer behavior is the growing trend toward preventive healthcare, with more individuals opting for early interventions to manage their blood sugar levels before the need for insulin arises. Non-insulin therapies are often prescribed as first-line treatments for newly diagnosed patients, especially those who are in the early stages of Type 2 diabetes. This trend is particularly prevalent in younger, tech-savvy patients who are more inclined to seek out the latest advancements in medicine and prioritize convenience and long-term health outcomes. Overall, consumer preferences are playing a critical role in shaping the non-insulin diabetes therapeutics market by pushing for treatments that are not only effective but also user-friendly and aligned with modern lifestyle demands.

What Is Driving The Growth Of The Non-Insulin Therapeutics Market?

The growth in the non-insulin diabetes therapeutics market is driven by several factors, including technological advancements, a growing diabetic population, and evolving healthcare policies. Technological innovations such as extended-release formulations, combination drugs, and continuous glucose monitoring devices that work in tandem with non-insulin therapies are playing a pivotal role in market expansion. These advancements have improved the efficacy and convenience of non-insulin treatments, making them more attractive to both patients and healthcare providers. Additionally, the rise in Type 2 diabetes cases, especially in emerging economies where urbanization and lifestyle changes have led to a surge in obesity rates, has significantly expanded the addressable market for these therapies. In regions such as Asia-Pacific and Latin America, where healthcare infrastructure is improving and access to modern treatments is growing, non-insulin diabetes therapies are gaining ground. Moreover, as the global population ages, the prevalence of diabetes continues to rise, further driving demand for effective and accessible treatments that can be easily integrated into patients' daily routines.

Furthermore, evolving healthcare policies are playing a crucial role in driving the market. Many governments and healthcare organizations are actively promoting the use of non-insulin therapies as part of broader public health campaigns aimed at managing the diabetes epidemic. For instance, policies that encourage early diagnosis and preventive care are leading to the increased use of non-insulin medications as first-line therapies for newly diagnosed patients. In addition, the growing emphasis on value-based healthcare models, where treatments are evaluated not just on their efficacy but also on their long-term cost-effectiveness, is boosting the adoption of non-insulin drugs, which are often seen as more cost-efficient compared to insulin-based therapies. Moreover, many insurance companies are expanding coverage for non-insulin medications, making them more accessible to a wider range of patients. This combination of technological innovation, demographic shifts, and supportive policy frameworks is propelling the growth of the non-insulin diabetes therapeutics market on a global scale, making it one of the most dynamic and fast-evolving segments in the pharmaceutical industry.

Select Competitors (Total 48 Featured) -

• 3SBio, Inc.
• Abbott Laboratories, Inc.
• Alkem Laboratories Limited
• AstraZeneca Plc
• Boehringer Ingelheim International GmbH
• Eli Lilly and Company
• Gemopharm LLC
• Merck KGaA
• Novo Nordisk A/S
• Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Non-Insulin Diabetes Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Global Prevalence of Diabetes Drives Demand for Non-Insulin Therapeutics
  • Advances in GLP-1 Receptor Agonists Bodes Well for Non-Insulin Therapeutics Market
  • Rising Demand for SGLT2 Inhibitors Drives Adoption of Non-Insulin Therapeutics
  • Growing Focus on Weight Management in Diabetes Care Spurs Market Expansion
  • Increasing Adoption of Non-Pharmacological Interventions Expands Treatment Options
  • Awareness of Long-Term Complications of Insulin Fuels Growth in Non-Insulin Solutions
  • Development of Next-Generation Anti-Diabetic Drugs Strengthens Business Case for Growth
  • Expanding Geriatric Population Accelerates Demand for Non-Insulin Solutions
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Non-Insulin Diabetes Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Non-Insulin Diabetes Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for DPP4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for DPP4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for DPP4 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for GLP-1 Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for GLP-1 Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for GLP-1 Receptor Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for SGLT2 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for SGLT2 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 17: USA Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 18: USA Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: USA 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 20: Canada Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 21: Canada Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: Canada 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• JAPAN
  • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 23: Japan Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 24: Japan Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: Japan 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• CHINA
  • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 26: China Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: China Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: China 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• EUROPE
  • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 30: Europe Historic Review for Non-Insulin Diabetes Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: Europe 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 32: Europe Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Europe Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: Europe 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• FRANCE
  • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 35: France Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: France Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: France 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• GERMANY
  • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 38: Germany Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Germany Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Germany 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 41: Italy Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Italy Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Italy 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 44: UK Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: UK Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: UK 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 47: Spain Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Spain Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Spain 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 50: Russia Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Russia Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Russia 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Rest of Europe Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Rest of Europe 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 57: Asia-Pacific Historic Review for Non-Insulin Diabetes Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Asia-Pacific 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Asia-Pacific Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Asia-Pacific 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 62: Australia Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Australia Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: Australia 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• INDIA
  • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 65: India Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: India Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: India 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 68: South Korea Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: South Korea Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: South Korea 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Rest of Asia-Pacific Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Rest of Asia-Pacific 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 74: Latin America Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 75: Latin America Historic Review for Non-Insulin Diabetes Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Latin America 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 77: Latin America Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Latin America Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: Latin America 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 80: Argentina Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Argentina Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: Argentina 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 83: Brazil Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Brazil Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: Brazil 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 86: Mexico Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Mexico Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Mexico 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Rest of Latin America Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Rest of Latin America 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 92: Middle East Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 93: Middle East Historic Review for Non-Insulin Diabetes Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Middle East 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 95: Middle East Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Middle East Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Middle East 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 98: Iran Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Iran Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Iran 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 101: Israel Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Israel Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Israel 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Saudi Arabia Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Saudi Arabia 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 107: UAE Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: UAE Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: UAE 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Rest of Middle East Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: Rest of Middle East 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
• AFRICA
  • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 113: Africa Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Africa Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: Africa 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030

IV. COMPETITION